7599 ANAGRAM DR, EDEN PRAIRIE, MN
Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order
Announces Successful Robotic-Assisted Drug Delivery Using Next-Generation StereoCED™ Platform
Reports Fiscal Q3 2026 Financial Results, Revenues Increase 16% YoY to $2.0 Million; Gross Margins Expand to 59.9%
NeuroOne Medical Technologies Files Updated Prospectus for $13.4M Offering
Announces Restatement of Financial Results for Quarter Ending March 31, 2026
Reports Fiscal Q2 2026 Financial Results and Provides Corporate Business Update
Other Events
CFO Retirement - Ronald McClurg to Step Down; Christopher Volker Appointed
Q3
Amended Quarterly Report
Q2
Q1
Amended Annual Report
FY 2025
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
PRER14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Amended Schedule 13G - Ownership Report
Specialized Disclosure Report